GlassScriptPhysician profile
David A Zimmerman
NPI 1134181472
$3,147.18
in general payments reported to CMS, 2019-2025
25 companies · $64.88 in 2025
The $64.88 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $508 · 2021: $270 · 2022: $632 · 2023: $327 · 2024: $27.95 · 2025: $64.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406 · Entertainment: $13.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.15 |
| Entertainment | $13.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $784.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $304.63 | 2019-2021 | |
| Amgen INC. | $297.38 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $250.81 | 2019-2023 | Eliquis |
| Pfizer INC. | $195.54 | 2019-2023 | |
| Heartflow, INC. | $162.14 | 2022 | |
| Amarin Pharma, INC. | $131.11 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.26 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $117.02 | 2019-2023 | |
| Esperion Therapeutics, INC. | $116.51 | 2020-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $105.84 | 2019-2023 | Brilinta |
| Boston Scientific Corporation | $100.43 | 2019-2024 | Watchman Access System, Ekosonic |
| Cvrx, INC. | $95.23 | 2022-2024 | Barostim Neo System |
| W. L. Gore & Associates, INC. | $84.66 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $63.99 | 2022-2023 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.01 | 2021-2022 | |
| United Therapeutics Corporation | $36.16 | 2020-2022 | |
| Gilead Sciences, INC. | $29.02 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $25.19 | 2023 | Uptravi |
| Novo Nordisk INC | $23.11 | 2022 | |
| Lundbeck LLC | $18.46 | 2019 | |
| Optos, INC. | $13.56 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Regeneron Healthcare Solutions, INC. | $12.29 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.27 | 2020 | |
| Edwards Lifesciences Corporation | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.